Rigel Pharmaceuticals Inc
RIGL
Company Profile
Business description
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
Contact
611 Gateway Boulevard
Suite 900
South San FranciscoCA94080
USAT: +1 650 624-1100
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
174
Stocks News & Analysis
stocks
This ASX supermarkets business is now underperforming its largest competitor
Competition restrains long-term margins.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,923.80 | 30.30 | -0.34% |
| CAC 40 | 8,031.89 | 82.95 | -1.02% |
| DAX 40 | 24,202.43 | 89.95 | -0.37% |
| Dow JONES (US) | 49,499.27 | 152.87 | -0.31% |
| FTSE 100 | 10,363.93 | 14.89 | -0.14% |
| HKSE | 26,095.88 | 319.35 | 1.24% |
| NASDAQ | 25,114.44 | 222.13 | 0.89% |
| Nikkei 225 | 59,513.12 | 228.20 | 0.38% |
| NZX 50 Index | 13,097.68 | 58.48 | 0.45% |
| S&P 500 | 7,230.12 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,697.10 | 28.50 | -0.33% |
| SSE Composite Index | 4,112.16 | 4.65 | 0.11% |